## INDEX

References given are to page numbers.

## ACCOUNTING FOR INTELLECTUAL PROPERTY ASSET TRANSACTIONS

- acquisition of intangible assets, 199
- assessing value of intellectual property assets, 202-203
- intangible assets in business combinations, *see* INTANGIBLE ASSETS IN BUSINESS COMBINATIONS
- intellectual property as intangible assets, 184-186
  - • initial recognition of intangible asset, 184-185
  - • subsequent measurement of intangible asset, 185-186
- internally-generated intangible assets, 186-187
- introduction, 183
- subsequent measurement, 200-202
  - • cash-generating units, 200
  - • impairment testing, 200-201
  - • value in use (VIU) vs. fair value less costs of disposal (FVLCOD), 201-202

### ADVANCED DUE DILIGENCE

#### See also DUE DILIGENCE, INTELLECTUAL PROPERTY

- clearance search, 85
- enforcement assessment, 85
- freedom to operate assessment, 85
- generally, 84
- patentability assessment, 86
- state of the art searches, 85
- validity assessment, 85-86

## BUSINESS ASSESSMENT OF INNOVATION FOR PROTECTION

See also COMMERCIALIZING INTELLECTUAL ASSETS

- change in environment or macro-economics, 38
- competition, 40
- existing IP protection, 39
- exit strategy, 40-41
- financial projections, 40
- how problem was solved in past, 38
- innovation, 39
- marketing and sales strategy, 39
- need for funds, 40
- overall description, 38

#### BUSINESS ASSESSMENT OF INNOVATION FOR PROTECTION -

continued

- partners, 40
- problem to solve, 38
- revenue model, 40
- successes, 39
- target market, 38-39
- team, 40

### COMMERCIAL VALUE AND PATENT VALIDITY

- ambiguity, 295-296
- anticipation, 290-291
- claims broader than invention made or disclosed, 301-303
- double patenting, 299-301
- *Gillette* defence, 299
- insufficiency, 293-295
- introduction, 287-289
- obviousness, 291-293
- patent claims, 289-290
- selection patents, 303-304
- special considerations with respect to pharmaceuticals and biologics, 304-306
  - • Patented Medicines (Notice of Compliance) Regulations, 304-306
  - • Patented Medicines Prices Review Board, 306
- strength of patent, 307
- utility and sound prediction, 297-298

## COMMERCIALIZATION ORGANIZATION

## See also COMMERCIALIZING INTELLECTUAL ASSETS

- general, 42-44
- rationale for commercialization organizations, 44
- steps of working with commercialization organization, 45-48
  - • assessment, 45-46
  - • communications, 48
  - • ending relationship, 48
  - • engagement, 45
  - • marketing, 46
  - • preliminary education, 45
  - • protection, 46
  - • start up, 47-48

## COMMERCIALIZING INTELLECTUAL ASSETS

• business assessment of innovation for protection, *see* BUSINESS ASSESSMENT OF INNOVATION FOR PROTECTION

#### **COMMERCIALIZING INTELLECTUAL ASSETS** — *continued*

- commercialization organization, *see* COMMERCIALIZATION ORGANIZATION
- confidentiality or non-disclosure arrangements, see CONFIDENTIALITY OR NON-DISCLOSURE ARRANGEMENTS
- introduction, 17-18
  - • commercialization explained, 18
  - • consequences of commercialization, 18
- invention disclosure program, 41
- key elements of commercialization process, 18-26
  - • commercialization, 25-26
    - • development, 22-24
    - • discovery, 21-22
    - • interactive assessment, 19-21
    - • pre-commercialization, 24-25
- legal assessment of innovation for protection, *see* LEGAL ASSESSMENT OF INNOVATION FOR PROTECTION
- proto-type development, 41-42

## CONFIDENTIALITY OR NON-DISCLOSURE ARRANGEMENTS

See also COMMERCIALIZING INTELLECTUAL ASSETS

- common exclusions, 32
- confidentiality is not privacy, 34
- damages limitations, 34
- definition of information, 28
- duration of obligations, 31
- form of agreement, 27
- generally, 26-27
- government contracts, 262-263
- no implied license, 33
- non-disclosure obligation and restrictions on use, 29-30
- parties, 27-28
- permitted disclosure to others, 30-31
- purpose of disclosure, 28
- requirements of formality, 29
- return of information, 33
- scope of duty, 30
- unusual terms, 33-34
- universities, 237-238, 240-241

## DIRECT FUNDING

See also PUBLIC POLICY OPTIONS TO INCENT INNOVATION

- early-stage funding programs, 278-280
  - • Business Innovation Access Program, 279-280
  - • Canada Accelerator and Incubator Program, 278-279

#### **DIRECT FUNDING** — *continued*

- generally, 278
- grants for filing, 280-281
  - • China Article 16 reward and remuneration, 281
  - • Hong Kong Patent Application Grant, 280-281
  - • Québec First Patent program, 280

## DUE DILIGENCE, INTELLECTUAL PROPERTY

- advanced due diligence, see ADVANCED DUE DILIGENCE
- external searches, *see* EXTERNAL SEARCHES
- internal due diligence, see INTERNAL DUE DILIGENCE
- introduction, 65-68
  - • intellectual property audit, 66
  - • transactional intellectual property due diligence, 66-68
- reporting, 86
- scope of due diligence effort, 68-70

#### **EXPENSES**

See also TAXATION OF INTELLECTUAL PROPERTY TRANSACTIONS

- capital expenses, 172-174
  - • capital cost allowance, 173-174
  - • eligible capital expenditures, 174
- current expenses, 172
- generally, 172
- research and development expenses, 174-177
  - • federal investment tax credits, 176-177
  - • provincial tax credits, 177
  - • scientific (SR&ED expenses), 175-176

## **EXTERNAL SEARCHES**

## See also DUE DILIGENCE, INTELLECTUAL PROPERTY

- additional factors affecting searching, 73-74
- defining where to search, 71-72
- generally, 70-71
- limiting scope of searching, 74-76
  - • entities, 75-76
  - • intellectual property offices, 75
  - • reporting scope, 76
  - • type of intellectual property, 74-75

#### **INSOLVENCY, LICENSES**

See also LICENSING

- insolvency generally, 106-107
- law reform in Canada, 108-110
- licensee's insolvency, 107

#### **INSOLVENCY, LICENSES** — *continued*

• licensor's insolvency, 107-108

## INSURING AGAINST LITIGATION-BASED TRANSACTION RISK

- coverage for intellectual property infringement claims under non-IP policies, 213-217
  - IP coverage under commercial general liability (CGL) policy, 213-217
- defense and indemnity agreements, 224-225
- duty to defend, 211-213
- information technology policies, 218
- introduction, 205-207
- IP coverage under directors and officers liability policies, 217-218
- IP-specific coverage, 218-224
  - • defence (liability) coverage, 220-221
  - • enforcement (pursuit) coverage, 221-222
  - • IP representations and warranties insurance, 224
  - • multi-peril coverage, 222-223
  - • wrap around policies, 223
- litigation risk, insuring against, 225
- structure and terminology of insurance policies, 207-211
  - • conditions, 211
  - • coverage or insuring agreement, 210-211
  - • declarations, 208-210
  - • endorsements, 211
  - • exclusions, 210

# INTANGIBLE ASSETS, see ACCOUNTING FOR INTELLECTUAL PROPERTY ASSET TRANSACTIONS

#### INTANGIBLE ASSETS IN BUSINESS COMBINATIONS

See also ACCOUNTING FOR INTELLECTUAL PROPERTY ASSET TRANSACTIONS

- assessing allocation between identifiable intangible assets and goodwill, 196-199
- fair value versus fair market value, 190-191
- goodwill versus intangible assets, 189-190
- market participant concept, 192-193
  - • measuring fair value using income approach, 192-193
  - valuing "dormant" intangible assets, 193
- market participants, 191
- overview, 187-189
- rates of return and discount rate selection, 196
- tax amortization benefits, 196
- valuation of business enterprise versus valuation of identifiable intangible assets, 193-194

### **INTANGIBLE ASSETS IN BUSINESS COMBINATIONS** — continued

- valuation of intangible assets, 194-195
  - • multi-period excess earnings method (MEEM), 194-195
  - • relief-from-royalty method, 195
- valuation techniques in financial reporting context, 191-192
  - • cost approach, 192
  - • income approach, 191
  - • market approach, 192

#### INTERNAL DUE DILIGENCE

## See also DUE DILIGENCE, INTELLECTUAL PROPERTY

- generally, 76-77
- information disclosure request, 77-80
  - • identify material IP and registrations, 77
  - • intellectual property litigation, 78
  - • licenses, 78
  - • personal information privacy, 78-80
- intellectual property agreement review, 82-84
- internal intellectual property file review, 80-81
- interviews, 81-82
- limitations on internal assessment, 84

#### **LEGAL ASSESSMENT OF INNOVATION FOR PROTECTION** *See also* COMMERCIALIZING INTELLECTUAL ASSETS

- copyright, 36
- generally, 34-35
- industrial design, 37
- patents, 35-36
- trade secrets, 37-38
- trademarks, 36-37

## LICENSE AGREEMENTS, KEY ELEMENTS

- See also LICENSING
  - exclusivity, 92-93
  - field of use, 93-94
  - grant of license, 91-92
  - subject matter, 93
  - sublicense rights, 95
  - term, 94
  - territory, 94-95

#### LICENSE AGREEMENTS, UNIVERSITIES

See also UNIVERSITIES, ACQUIRING INTELLECTUAL

- PROPERTY RIGHTS FROM
- consideration, 245-246
- exclusivity, 246

#### LICENSE AGREEMENTS, UNIVERSITIES — continued

- generally, 242-243
- improvements, 246
- ownership, 243-244
- patent prosecution, 244-245
- specific terms and conditions of license agreement, 247-250
  - • additional research commitment/improvements, 249
  - • exclusive versus non-exclusive, 248
  - • milestones performance obligations, 248
  - • minimum annual royalties, 249-250
  - • nature of grant of rights, 247
  - • representations and warranties, 247
  - • royalties/compensation alternatives, 249
  - • subsequent improvements, 247-248

## LICENSING

- drafting licenses, 265-267
- indemnities, 104
- information disclosure request, 78
- insolvency, see INSOLVENCY, LICENSES
- key elements of license agreement, *see* LICENSE AGREEMENTS, KEY ELEMENTS
- license agreements must relate to specific IP rights, 90-91
- license explained, 87-88
- limitation of liability, 104-105
- parties to license, 88
- payment terms, see PAYMENT TERMS, LICENSES
- personal property, licenses as, 155
- representations and warranties, *see* REPRESENTATIONS AND WARRANTIES, LICENSES
- sale of licensed IP asset, 53
- strategic licensing, 100-102
- special cases, 110-114
  - • creative commons, 110-111
  - • freeware, shareware and open source, 111-114
- termination, see TERMINATION OF LICENSES
- why use license agreement, 88-90

## PAYMENT TERMS, LICENSES

See also LICENSING

- milestone payments, 95-96
- minimum payments, 96
- royalties, *see* ROYALTIES
- rule of thumb, 99-100
- upfront payments, 95

#### PUBLIC POLICY OPTIONS TO INCENT INNOVATION

- changes to patent laws / examination procedures, 284-286
  - green technology and accelerated patent examination programs, 284-286
- direct funding, see DIRECT FUNDING
- introduction, 269
- measuring results of public policy choices, 286
- second tier patent systems, *see* SECOND TIER PATENT SYSTEMS
- tax-based incentives, see TAX-BASED INCENTIVES

#### RECEIPTS

## See also TAXATION OF INTELLECTUAL PROPERTY

- TRANSACTIONS
- generally, 169
- income versus capital, 170-171
- payments based on production or use, 171-172

#### **REPRESENTATIONS AND WARRANTIES, LICENSES**

See also LICENSING

- generally, 102
- maintenance of intellectual property, 104
- non-infringement, 102-103
- performance, 103-104
- title, 102

### **ROYALTIES**

See also PAYMENT TERMS, LICENSES

- audit rights, 98-99
- generally, 96
- license agreements, universities, 249-250
- payment of royalties and similar amounts to non-residents, 178-180
- permitted deductions, 97
- report, 98
- reporting period, 98
- royalty base, 97
- royalty rate, 97-98
- royalty sale, 54-55

#### SECOND TIER PATENT SYSTEMS

See also PUBLIC POLICY OPTIONS TO INCENT INNOVATION

- Australian innovation patents, 283
- Chinese utility models, 283
- generally, 282
- German utility models, 282

#### **SECOND TIER PATENT SYSTEMS** — *continued*

- Japanese utility models, 282-283
- pros and cons of second tier patent systems, 284

# SECURITY IN INTELLECTUAL PROPERTY ASSETS, TAKING AND ENFORCING

- Bank Act security, 161
- commitment letters, 147-149
  - • legal opinion, 149
- creation of security interests, *see* SECURITY INTERESTS, CREATION OF
- enforcing security in bankruptcy, 164-165
- issues relating to licenses in default and bankruptcy proceedings, 166-167
- introduction, 143
- lenders' criteria for acceptance of intangible assets as collateral, 143-147
  - • identifiability, 144
  - • liquidity, 147
  - • robustness, 146
  - • title, 144-146
  - • valuability, 147
- lender's remedies under hypothec (Québec), 163-164
- lender's remedies under security agreement, 162-163
  - • receivers, 162-163
  - • receiver's ability to pass good title, 163
- loan agreements, 147-151
  - • conditions precedent, 148
  - • legal opinion, 149
  - representations, warranties and covenants in loan agreement, 149-151
- necessity of registering under federal statutes, *see* SECURITY INTEREST UNDER FEDERAL STATUTES, REGISTERING
- risks, 167-168
- term sheets, 147

## SECURITY INTERESTS, CREATION OF

See also SECURITY IN INTELLECTUAL PROPERTY ASSETS, TAKING AND ENFORCING

- generally, 151
- multiple jurisdictions and multiple registrations, 156-157
- provincial Personal Property Security Acts, 151-155
  - • after-acquired property, 155
  - • describing collateral, 154
  - • licenses as personal property, 155
  - • scope of security interest, 153-154

#### **SECURITY INTERESTS, CREATION OF** — *continued*

• security interests in province of Québec, 156

#### SECURITY INTERESTS UNDER FEDERAL STATUTES, REGISTERING

See also SECURITY IN INTELLECTUAL PROPERTY ASSETS,

- TAKING AND ENFORCING
- Copyright Act, 159-160
- Industrial Design Act, 160
- Integrated Circuit Topography Act, 160
- necessity of, 157-158
- Patent Act, 159
- Plant Breeders' Rights Act, 161
- Trade-Marks Act, 160

## STRATEGIC AND REVENUE-GENERATING ASPECTS OF INTELLECTUAL PROPERTY ASSETS

- growth in registration of intellectual property rights, 6-7
- issues arising in intellectual property transactions, 14-15
- intellectual property rights explained, 2-6
- introduction, 1
- sources of revenue, intellectual property rights as, 7-10
- strategic utility of intellectual property rights, *see* STRATEGIC UTILITY OF INTELLECTUAL PROPERTY RIGHTS

## STRATEGIC UTILITY OF INTELLECTUAL PROPERTY RIGHTS

See also STRATEGIC AND REVENUE-GENERATING ASPECTS

- OF INTELLECTUAL PROPERTY ASSETS
- alliance building, 12
- attracting investment, 12-13
- competitive intelligence, 12
- creating revenue-generating opportunities, 13
- defensive, 12
- generally, 11-13
- harassing competitors and limiting market entrants, 13
- satisfying shareholders, 13
- sectoral intelligence, 12

## TAXATION OF INTELLECTUAL PROPERTY TRANSACTIONS

- expenses, see EXPENSES
- introduction, 169
- non-residents, 177-182
  - • payment for services rendered in Canada, 180
  - • payment of royalties and similar amounts to non-residents, 178-180
  - • transfer pricing considerations, 181-182

## TAXATION OF INTELLECTUAL PROPERTY TRANSACTIONS -

continued

• receipts, see RECEIPTS

## **TAX-BASED INCENTIVES**

See also PUBLIC POLICY OPTIONS TO INCENT INNOVATION

- "back-end" incentives IP boxes, 272-273
- China's patent box, 277
- "front-end" incentives, 269-272
  - • R&D programs in China, 271-272
  - • R&D programs in Europe, 271
  - • "research or experimental expenditures" in United States, 270-271
  - • "SR&ED" tax incentives in Canada, 270
- generally, 269
- IP box concerns, 277-278
- IP boxes in Europe, 273-277
  - • eligible forms of income, 275-276
  - • qualifying IP, 274-275
  - • tax rate, 273
  - • treatment of IP-related expenses, 276-277
- pros and cons of "front-end" incentives, 272

## TECHNOLOGY TRANSFER AND GOVERNMENT

- conclusion, 267
- conflicts, 257
- contract drafting, 261-267
  - • collaboration agreement or CDRA, 263-265
  - confidentiality agreement / non-disclosure agreement, 262-263
  - • general, 261-262
  - • license, 265-267
  - • material transfer agreement, 262
- culture, 253-257
- introduction, 253
- law, 259-260
- research and development, 258-259

## **TERMINATION OF LICENSES**

- See also LICENSING
  - generally, 105
  - obligations on termination, 106
  - termination for breach, 105
  - termination for convenience, 105-106

#### TRANSACTIONS

- asset-backed securitization, 57-60
- back license, 52-53
- collateralization, 55-57
- introduction, 49-51
- license, 51-52
- reasons for entering into transactions, 64
- royalization, 60-63
- royalty sale, 54-55
- sale of licensed IP asset, 53

## UNIVERSITIES, ACQUIRING INTELLECTUAL PROPERTY RIGHTS FROM

- background perspectives, 231-232
- contract research agreement, 239-242
  - • confidentiality, 240-241
  - • publication by institution, 241-242
- hybrid license, 251
- indemnification, limitation on damages, 251-252
- license agreement, see LICENSE AGREEMENTS, UNIVERSITIES
- negotiation of license agreement, 252
- overview, 227-231
- patent prosecution/infringement/validity, 250-251
  - • infringement by licensee, 250
  - • prosecution, 250
  - • third party infringement, 251
- process to acquiring IP rights, 237-238
  - • initial steps, 237
  - • non-disclosure agreements, 237-238
- technical services agreement, 238-239
- university options, 232-236
  - • challenge to academic freedom, 235-236
  - • challenges generally, 232-235

## VALUATION OF INTELLECTUAL PROPERTY ASSETS

- intellectual property in context of business enterprise, 131-132
- intellectual property related litigation, 139-142
  - • infringement cases, 141-142
- introduction, 115
- price and value, difference between, 120
- valuation approaches, 125-131
  - • comparison of three approaches to valuation, 130-131
  - • cost approach, 126
  - • income approach, 125
  - • market approach, 126

#### VALUATION OF INTELLECTUAL PROPERTY ASSETS — continued

- valuation approaches applicable to intellectual property, 132-138
  - • cost savings method, 135
  - • direct methods, 134-137
  - • excess earnings and premium profit method, 134-135
  - • income approach method in valuation of intellectual property, 133-134
  - • indirect methods, 137-138
  - • relief from royalty method, 135-137
- valuation basis, 124-125
- valuation methods, 126-130
  - analyses of prior transactions of interests in subject entity/ asset, 129-130
  - • CCF method, 127-128
  - • DCF method, 126-127
  - • guideline public company method, 128-129
  - • precedent transactions method, 129
- valuation of business enterprise versus valuation of identifiable intangible assets, 193-194
- valuation of intangible assets, 194-195
  - • multi-period excess earnings method (MEEM), 194-195
  - • relief-from-royalty method, 195
- valuation principles, 118-120
  - • corroboration, 120
  - • minority and illiquidity, 120
  - • point in time, 119
  - • tangible asset backing, 120
  - • value is function of future expected cash flow, 119
- valuation process, 123-124
- valuation techniques in financial reporting context, 191-192
  - • cost approach, 192
  - • income approach, 191
  - • market approach, 192
- value definitions, 121-123
  - • fair market value, 121
  - • fair value, 122-123
  - • value to owner, 123
- when valuation is required, 115-118
  - • arm's length transactions, 116-117
  - • commercial litigation, 118
  - • financing, 118
  - • non-arm's length transactions, 117